PCI Biotech to present at the World Vaccine Congress 2015
Lysaker, April 8, 2015 – PCI Biotech will be presenting at the World Vaccine Congress 2015 at Walter E. Washington Convention Center, Washington D.C. In its 15th year, World Vaccine Congress remains the industry’s definitive vaccine industry conference and exhibition for major vaccine players and their respective senior level representatives.
The presentation “Photochemical internalisation (PCI) – an innovative technology for CTL-induction” will be held April 8 local time 10:10 and the company will be represented by Dr. Anders Høgset, CSO. The presentation will be available at PCI Biotech’s webpage under “News”.
About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI technology works by inducing triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities, such as small molecules, ADCs and siRNA. Two programs are currently in clinical development in patient populations with a high unmet medical need; recurrent head and neck cancer (phase II) and bile duct cancer (phase I/II).
The company is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs (Cytotoxic T Lymphocytes) by enhancing the MHC I antigen presentation of antigen presenting cells. When applied more specifically to the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines. PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.
For more information visit: www.pcibiotech.com
For further information, please contact
Ronny Skuggedal, CFO
rs@pcibiotech.no
Mobile: +47 9400 5757